<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791812</url>
  </required_header>
  <id_info>
    <org_study_id>22-3028-101</org_study_id>
    <nct_id>NCT05791812</nct_id>
  </id_info>
  <brief_title>Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE</brief_title>
  <acronym>ACTIVATE</acronym>
  <official_title>Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE - Heimanwendung Der Transkraniellen Gleichstromstimulation Zur Behandlung Der Chronischen Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a one-arm open-label interventional study with transcranial direct current stimulation&#xD;
      in an remote home-based setting with the aims to evaluate the feasibility (usability of the&#xD;
      device, compliance of patients, usability of the teletherapy), the effectiveness (clinical&#xD;
      ratings) and the compatability of this intervention in 20 patients with myalgic&#xD;
      encephalomyelitis/chronic fatigue syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability for the patients</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire [1-7, 26 items, the higher the better]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Usability for the handlers/clinicians</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire [1-7, 26 items, the higher the better]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of days out of 30 the patients used the device</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of days out of 30 the patients used the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who completed the treatment regularly</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of patients who completed the treatment regularly</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of responders according the the clinical global impression change score for patients in the per protocol analysis</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of responders according the the clinical global impression change score for patients in the per protocol analysis (range: 1-7; the lower the better)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect size for change of fatigue for patients in the per protocol analysis measured with the Bell Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Effect size for change of fatigue for patients in the per protocol analysis measured with the Bell Score (fatigue scale; 0-100; the higher the better)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect size for change of fatigue for patients in the per protocol analysis measured with the Chalder Fatigue Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Effect size for change of fatigue for patients in the per protocol analysis measured with the Chalder Fatigue Scale (fatigue scale; 0-33; the lower the better)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory</measure>
    <time_frame>18 weeks</time_frame>
    <description>Depression inventory (0-50, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation Quality of life scale (abbreviated Version) (WHOQOL-BREF)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Quality of life scale inventory (4-20, the higher the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression change</measure>
    <time_frame>18 weeks</time_frame>
    <description>Clinical Global Impression (1-7, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index</measure>
    <time_frame>18 weeks</time_frame>
    <description>sleep inventory (0-21, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>numeric analogue scale pain</measure>
    <time_frame>18 weeks</time_frame>
    <description>pain scale (0-10, the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>d2 test</measure>
    <time_frame>18 weeks</time_frame>
    <description>concentration test (percentiles; the higher the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>digital span</measure>
    <time_frame>18 weeks</time_frame>
    <description>memory test (percentiles; the higher the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chalder fatigue scale</measure>
    <time_frame>18 weeks</time_frame>
    <description>fatigue scale (0-33; the lower the better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bell score</measure>
    <time_frame>18 weeks</time_frame>
    <description>fatigue scale (0-100; the higher the better)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mA of tDCS for 20 min every weekday for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>home-based transcranial direct current stimulation (tDCS)</intervention_name>
    <description>2mA of tDCS for 20 min every weekday for six weeks</description>
    <arm_group_label>active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ME/CFS diagnosis according to the Canadian Consensus Criteria&#xD;
&#xD;
          -  residence near Regensburg and mother language German&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  stable medication if possible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications for transcranial direct current stimulation&#xD;
&#xD;
          -  certain neurological conditions as assessed by study physician&#xD;
&#xD;
          -  participation in another study&#xD;
&#xD;
          -  pregnancy and lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berthold Langguth</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Hebel</last_name>
    <phone>+49-941-1250</phone>
    <email>tobias.hebel@medbo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schecklmann</last_name>
    <phone>+49-941-1250</phone>
    <email>martin.schecklmann@medbo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Langguth</last_name>
      <phone>+49-941-941-2099</phone>
      <email>berthold.langguth@medbo.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Berthold Langguth, MD, Ph.D.</investigator_full_name>
    <investigator_title>Clinical Professor, MD, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>transcranial direct current stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>On demand possible.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

